当前位置：
X-MOL 学术
›
Xenobiotica
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective
Xenobiotica ( IF 1.8 ) Pub Date : 2023-11-26 , DOI: 10.1080/00498254.2023.2272180 Holger Scheible 1 , Hanno Schieferstein 1 , Ralf Schmidt 2 , Klaus Pusecker 1 , Ulrike Gradhand 1 , Sathej Gopalakrishnan 3 , Khalid Iqbal 3 , Jennifer Dong 2 , Reinaldo Jones 2 , Claudia Meli 4 , Jayaprakasam Bolleddula 2 , Martin Dyroff 2 , Katrin Georgi 1
Xenobiotica ( IF 1.8 ) Pub Date : 2023-11-26 , DOI: 10.1080/00498254.2023.2272180 Holger Scheible 1 , Hanno Schieferstein 1 , Ralf Schmidt 2 , Klaus Pusecker 1 , Ulrike Gradhand 1 , Sathej Gopalakrishnan 3 , Khalid Iqbal 3 , Jennifer Dong 2 , Reinaldo Jones 2 , Claudia Meli 4 , Jayaprakasam Bolleddula 2 , Martin Dyroff 2 , Katrin Georgi 1
Affiliation
Evobrutinib is a highly selective, covalent, central nervous system-penetrant Bruton’s tyrosine kinase (BTK) inhibitor, currently in Phase III trials for the treatment of relapsing multiple scleros...
中文翻译：
Evobrutinib 通往其主要代谢物 M463-2 的途径以及从生物转化和 DDI 角度的见解
Evobrutinib 是一种高选择性、共价、中枢神经系统渗透性布鲁顿酪氨酸激酶 (BTK) 抑制剂，目前处于治疗复发性多发性硬化症的 III 期试验中。
更新日期：2023-11-30
中文翻译：
Evobrutinib 通往其主要代谢物 M463-2 的途径以及从生物转化和 DDI 角度的见解
Evobrutinib 是一种高选择性、共价、中枢神经系统渗透性布鲁顿酪氨酸激酶 (BTK) 抑制剂，目前处于治疗复发性多发性硬化症的 III 期试验中。
京公网安备 11010802027423号